International Journal of Cardiology Cardiovascular Risk and Prevention最新文献

Letter to the Editor: Trends in coronary artery disease mortality among hyperlipidemic patients: Geographic, gender, and racial insights from CDC WONDER data (1999–2020) 致编辑的信：高脂血症患者冠状动脉疾病死亡率趋势：来自CDC WONDER数据的地理、性别和种族见解（1999-2020）

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-20 DOI: 10.1016/j.ijcrp.2026.200581

Mohamed Fawzi Hemida MD

引用次数: 0

The effect of COVID-19 pandemic on admission, management and mortality of pulmonary embolism in cancer patients 新冠肺炎大流行对肿瘤患者肺栓塞入院、治疗和死亡率的影响

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-17 DOI: 10.1016/j.ijcrp.2026.200580

Dror Magen , Adam Folman , Marlon V. Gatuz , Rami Abu Fanne , Ariel Roguin , Ofer Kobo

Background

Pulmonary embolism (PE) is a leading cause of morbidity among cancer patients. The COVID-19 pandemic introduced new challenges to healthcare delivery. This study aimed to evaluate the impact of the COVID-19 pandemic on PE-related hospitalizations, treatment, and in-hospital outcomes in patients with active cancer.

Methods

We conducted a retrospective analysis using the National Inpatient Sample database from 2016 to 2021. Patients with active cancer and a primary diagnosis of acute PE were categorized into three groups: pre-COVID-19 (2016–2019), peak COVID-19 (2020), and ongoing COVID-19 (2021). We compared baseline characteristics, in-hospital procedures, and clinical outcomes among these groups. Multivariable logistic regression was employed to assess associations between COVID-19 periods and outcomes.

Results

Among 170,630 patients with PE and cancer, admission rates decreased during the pandemic. Patients hospitalized during the COVID-19 pandemic more frequently presented with severe PE phenotypes, including saddle PE (9.7 % and 9.4 % vs. 7.5 %, p < 0.001) and acute cor pulmonale (8.4 % and 8.9 % vs. 5.9 %, p < 0.001). Thrombolysis-based therapies increased during the pandemic, whereas adjusted odds of catheter-directed embolectomy were lower. Despite more severe presentations, in-hospital mortality remained relatively stable (6.0 % pre-COVID-19, 6.0 % peak, 5.5 % ongoing; p = 0.004).

Conclusion

The COVID-19 pandemic led to decreased PE-related hospitalizations among cancer patients but was associated with more severe presentations and shifts in therapeutic strategies. Notably, in-hospital mortality remained stable, which may be consistent with maintained PE care pathways during the pandemic. These findings highlight the need for robust, adaptable healthcare systems to ensure continuity of care for high-risk populations during global health crises.

肺栓塞（PE）是癌症患者发病的主要原因。COVID-19大流行给医疗保健服务带来了新的挑战。本研究旨在评估COVID-19大流行对活动性癌症患者pe相关住院、治疗和住院结局的影响。方法采用2016 - 2021年全国住院患者样本数据库进行回顾性分析。初步诊断为急性PE的活动性癌症患者分为三组：COVID-19前期（2016-2019），COVID-19高峰（2020）和正在进行的COVID-19（2021）。我们比较了这些组的基线特征、住院程序和临床结果。采用多变量logistic回归评估COVID-19时期与结果之间的相关性。结果在170,630例PE合并癌症患者中，住院率在大流行期间有所下降。在COVID-19大流行期间住院的患者更频繁地出现严重的PE表型，包括鞍型PE（9.7%和9.4%对7.5%,p < 0.001）和急性肺脏（8.4%和8.9%对5.9%,p < 0.001）。在大流行期间，以溶栓为基础的治疗增加，而经调整的导管导向栓塞切除术的几率较低。尽管出现了更严重的症状，但住院死亡率保持相对稳定（covid -19前6.0%，峰值6.0%，持续5.5%;p = 0.004）。结论2019冠状病毒病大流行导致癌症患者pe相关住院率下降，但与更严重的表现和治疗策略的转变有关。值得注意的是，住院死亡率保持稳定，这可能与大流行期间保持的体育护理途径一致。这些发现突出表明，需要建立健全、适应性强的卫生保健系统，以确保在全球卫生危机期间对高危人群的持续护理。

{"title":"The effect of COVID-19 pandemic on admission, management and mortality of pulmonary embolism in cancer patients","authors":"Dror Magen , Adam Folman , Marlon V. Gatuz , Rami Abu Fanne , Ariel Roguin , Ofer Kobo","doi":"10.1016/j.ijcrp.2026.200580","DOIUrl":"10.1016/j.ijcrp.2026.200580","url":null,"abstract":"<div><h3>Background</h3><div>Pulmonary embolism (PE) is a leading cause of morbidity among cancer patients. The COVID-19 pandemic introduced new challenges to healthcare delivery. This study aimed to evaluate the impact of the COVID-19 pandemic on PE-related hospitalizations, treatment, and in-hospital outcomes in patients with active cancer.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis using the National Inpatient Sample database from 2016 to 2021. Patients with active cancer and a primary diagnosis of acute PE were categorized into three groups: pre-COVID-19 (2016–2019), peak COVID-19 (2020), and ongoing COVID-19 (2021). We compared baseline characteristics, in-hospital procedures, and clinical outcomes among these groups. Multivariable logistic regression was employed to assess associations between COVID-19 periods and outcomes.</div></div><div><h3>Results</h3><div>Among 170,630 patients with PE and cancer, admission rates decreased during the pandemic. Patients hospitalized during the COVID-19 pandemic more frequently presented with severe PE phenotypes, including saddle PE (9.7 % and 9.4 % vs. 7.5 %, p < 0.001) and acute cor pulmonale (8.4 % and 8.9 % vs. 5.9 %, p < 0.001). Thrombolysis-based therapies increased during the pandemic, whereas adjusted odds of catheter-directed embolectomy were lower. Despite more severe presentations, in-hospital mortality remained relatively stable (6.0 % pre-COVID-19, 6.0 % peak, 5.5 % ongoing; p = 0.004).</div></div><div><h3>Conclusion</h3><div>The COVID-19 pandemic led to decreased PE-related hospitalizations among cancer patients but was associated with more severe presentations and shifts in therapeutic strategies. Notably, in-hospital mortality remained stable, which may be consistent with maintained PE care pathways during the pandemic. These findings highlight the need for robust, adaptable healthcare systems to ensure continuity of care for high-risk populations during global health crises.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200580"},"PeriodicalIF":2.1,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extent and predictors of guideline-directed medical therapy optimization during cardiac rehabilitation in patients with heart failure 心力衰竭患者心脏康复过程中指导药物治疗优化的程度和预测因素

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-09 DOI: 10.1016/j.ijcrp.2026.200579

Corentin Nicolas , Nicolas Girerd , Kevin Duarte , Olivier Huttin , Karim Djaballah , Jerome Felloni , Guillaume Baudry , Luca Monzo

Background

Cardiac rehabilitation (CR) may offer a structured framework for guideline-directed medical therapy (GDMT) optimization, but its real-world impact is uncertain. We aimed to quantify GDMT optimization and identify its clinical predictors during CR.

Methods

This retrospective single-centre study included patients hospitalized for acute HF with reduced (HFrEF) or mildly reduced (HFmrEF) ejection fraction who subsequently underwent first inpatient or ambulatory CR at Nancy University Hospital (2021–2024). Changes in GDMT optimization were evaluated using the HF prescription and the KCMO scores and expressed as adjusted standardized differences (ASD). Multivariable linear regression identified independent predictors of optimization.

Results

Among the 106 patients included (84 % HFrEF, mean age 59 years; 75 % male), baseline GDMT use was high, but doses were suboptimal. During CR, significant uptitration occurred across all major drug classes, including angiotensin receptor–neprilysin inhibitors (ASD: +22 %), beta-blockers (ASD: +21 %), mineralocorticoid receptor antagonists (ASD: +43 %), and sodium–glucose cotransporter 2 inhibitors (ASD: +45 %) (all p < 0.001). Overall GDMT optimization improved significantly, as evidenced by increases in both the KCMO (ASD: +39.9) and HF prescription (ASD: +1.27) scores (both p < 0.001), with consistent effects across inpatient and ambulatory settings. In multivariable analysis, higher loop-diuretic dose and prior treatment by HF specialists were associated with less optimization, whereas hypertension predicted greater intensification.

Conclusions

Cardiac rehabilitation after HF hospitalization promoted substantial GDMT optimization, especially in hypertensive patients. Higher loop-diuretic dose at admission predicted less optimization, suggesting that minimizing diuretic doses may ease GDMT titration.

心脏康复（CR）可能为指导医学治疗（GDMT）优化提供了一个结构化框架，但其实际影响尚不确定。我们的目的是量化GDMT优化并确定其在CR期间的临床预测因素。方法本回顾性单中心研究纳入了因急性心衰（HFrEF）或轻度（HFmrEF）射血分数降低而住院的患者，这些患者随后在南希大学医院（2021-2024）首次住院或门诊CR。使用HF处方和KCMO评分评估GDMT优化的变化，并以调整的标准化差异（ASD）表示。多变量线性回归识别优化的独立预测因子。结果在纳入的106例患者中（84% HFrEF，平均年龄59岁，75%男性），基线GDMT使用较高，但剂量不够理想。在CR期间，所有主要药物类别均出现显著升高，包括血管紧张素受体-神经球蛋白抑制剂（ASD: + 22%）、β受体阻滞剂（ASD: + 21%）、矿皮质激素受体拮抗剂（ASD: + 43%）和钠-葡萄糖共转运蛋白2抑制剂（ASD: + 45%）（均p <； 0.001）。总体GDMT优化显著改善，KCMO （ASD: +39.9）和HF处方（ASD: +1.27）评分均增加（p < 0.001），在住院和门诊环境中效果一致。在多变量分析中，较高的利尿剂剂量和先前心衰专科医生的治疗与较少的优化相关，而高血压预测更大的强化。结论心衰住院后的心脏康复促进了GDMT的显著优化，尤其是高血压患者。入院时较高的利尿剂剂量预测较少的优化，提示尽量减少利尿剂剂量可以缓解GDMT滴定。

{"title":"Extent and predictors of guideline-directed medical therapy optimization during cardiac rehabilitation in patients with heart failure","authors":"Corentin Nicolas , Nicolas Girerd , Kevin Duarte , Olivier Huttin , Karim Djaballah , Jerome Felloni , Guillaume Baudry , Luca Monzo","doi":"10.1016/j.ijcrp.2026.200579","DOIUrl":"10.1016/j.ijcrp.2026.200579","url":null,"abstract":"<div><h3>Background</h3><div>Cardiac rehabilitation (CR) may offer a structured framework for guideline-directed medical therapy (GDMT) optimization, but its real-world impact is uncertain. We aimed to quantify GDMT optimization and identify its clinical predictors during CR.</div></div><div><h3>Methods</h3><div>This retrospective single-centre study included patients hospitalized for acute HF with reduced (HFrEF) or mildly reduced (HFmrEF) ejection fraction who subsequently underwent first inpatient or ambulatory CR at Nancy University Hospital (2021–2024). Changes in GDMT optimization were evaluated using the HF prescription and the KCMO scores and expressed as adjusted standardized differences (ASD). Multivariable linear regression identified independent predictors of optimization.</div></div><div><h3>Results</h3><div>Among the 106 patients included (84 % HFrEF, mean age 59 years; 75 % male), baseline GDMT use was high, but doses were suboptimal. During CR, significant uptitration occurred across all major drug classes, including angiotensin receptor–neprilysin inhibitors (ASD: +22 %), beta-blockers (ASD: +21 %), mineralocorticoid receptor antagonists (ASD: +43 %), and sodium–glucose cotransporter 2 inhibitors (ASD: +45 %) (all p < 0.001). Overall GDMT optimization improved significantly, as evidenced by increases in both the KCMO (ASD: +39.9) and HF prescription (ASD: +1.27) scores (both p < 0.001), with consistent effects across inpatient and ambulatory settings. In multivariable analysis, higher loop-diuretic dose and prior treatment by HF specialists were associated with less optimization, whereas hypertension predicted greater intensification.</div></div><div><h3>Conclusions</h3><div>Cardiac rehabilitation after HF hospitalization promoted substantial GDMT optimization, especially in hypertensive patients. Higher loop-diuretic dose at admission predicted less optimization, suggesting that minimizing diuretic doses may ease GDMT titration.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200579"},"PeriodicalIF":2.1,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145925911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colchicine therapy in transcatheter aortic valve replacement: Modulating inflammation and outcomes 秋水仙碱治疗经导管主动脉瓣置换术：调节炎症和结果

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-08 DOI: 10.1016/j.ijcrp.2026.200575

Hamza A. Abdul-Hafez , Ameer Awashra , Malik Ahmad , Abdullah Raed Hawawrah , Bayan Mahafdah , Mohammed AbuBaha , Ibrahim Alazizi , Abdalhakim Shubietah , Mohamed S. Elgendy , Ahmed Emara

Background

Transcatheter aortic valve replacement (TAVR) is frequently accompanied by inflammation-related complications, including conduction disturbances, atrial fibrillation, and subclinical leaflet thrombosis. Colchicine, with its anti-inflammatory and antithrombotic properties, has emerged as a potential adjunctive therapy to mitigate these post-procedural events. However, its specific role in the TAVR population remains insufficiently defined.

Methods

A narrative review approach was used. Searches of PubMed, Scopus, Web of Science, and Google Scholar were performed through September 2025 using terms related to “transcatheter aortic valve replacement,” “TAVR,” and “colchicine.” Randomized trials, observational studies, mechanistic investigations, and guideline documents were screened. Findings were organized thematically to summarize mechanisms, therapeutic rationale, and clinical outcomes.

Results

Only one randomized controlled trial and one observational study have directly evaluated colchicine after TAVR. Both demonstrated reductions in inflammatory biomarkers and signals toward improved conduction-related parameters, but clinical endpoints such as pacemaker implantation, sustained arrhythmias, and imaging-confirmed leaflet thrombosis remain insufficiently studied. Mechanistic and perioperative cardiac evidence from non-TAVR settings supports colchicine’s potential by targeting inflammasome activity, microtubule regulation, and early thrombo-inflammatory remodeling.

Conclusions

Colchicine is a promising adjunctive strategy for attenuating inflammation-related complications after TAVR. Its multimodal actions align with the pathways implicated in conduction disturbances, atrial fibrillation, and leaflet thrombosis. However, current evidence is preliminary, with only two post-TAVR intervention studies available. Larger trials are needed to determine whether colchicine can translate mechanistic advantages into clinically meaningful improvements in post-TAVR outcomes.

经导管主动脉瓣置换术（TAVR）经常伴有炎症相关并发症，包括传导障碍、心房颤动和亚临床小叶血栓形成。秋水仙碱具有抗炎和抗血栓特性，已成为减轻这些术后事件的潜在辅助疗法。然而，其在TAVR人群中的具体作用仍未得到充分界定。方法采用叙事回顾法。到2025年9月，我们对PubMed、Scopus、Web of Science和谷歌Scholar进行了搜索，使用与“经导管主动脉瓣置换术”、“TAVR”和“秋水仙碱”相关的术语。筛选随机试验、观察性研究、机制调查和指南文件。研究结果按主题组织，以总结机制、治疗原理和临床结果。结果只有一项随机对照试验和一项观察性研究直接评价了秋水仙碱在TAVR后的作用。两者均显示炎症生物标志物和传导相关参数改善的信号减少，但临床终点，如起搏器植入、持续心律失常和影像学证实的小叶血栓形成仍未得到充分研究。来自非tavr设置的机械和围手术期心脏证据支持秋水仙碱通过靶向炎性体活性、微管调节和早期血栓炎性重塑的潜力。结论水蛭碱是减轻TAVR术后炎症相关并发症的一种有前景的辅助策略。它的多模态作用与传导障碍、心房颤动和小叶血栓形成的通路一致。然而，目前的证据是初步的，只有两项tavr后干预研究。需要更大规模的试验来确定秋水仙碱是否能将机制优势转化为tavr后临床有意义的改善。

{"title":"Colchicine therapy in transcatheter aortic valve replacement: Modulating inflammation and outcomes","authors":"Hamza A. Abdul-Hafez , Ameer Awashra , Malik Ahmad , Abdullah Raed Hawawrah , Bayan Mahafdah , Mohammed AbuBaha , Ibrahim Alazizi , Abdalhakim Shubietah , Mohamed S. Elgendy , Ahmed Emara","doi":"10.1016/j.ijcrp.2026.200575","DOIUrl":"10.1016/j.ijcrp.2026.200575","url":null,"abstract":"<div><h3>Background</h3><div>Transcatheter aortic valve replacement (TAVR) is frequently accompanied by inflammation-related complications, including conduction disturbances, atrial fibrillation, and subclinical leaflet thrombosis. Colchicine, with its anti-inflammatory and antithrombotic properties, has emerged as a potential adjunctive therapy to mitigate these post-procedural events. However, its specific role in the TAVR population remains insufficiently defined.</div></div><div><h3>Methods</h3><div>A narrative review approach was used. Searches of PubMed, Scopus, Web of Science, and Google Scholar were performed through September 2025 using terms related to “transcatheter aortic valve replacement,” “TAVR,” and “colchicine.” Randomized trials, observational studies, mechanistic investigations, and guideline documents were screened. Findings were organized thematically to summarize mechanisms, therapeutic rationale, and clinical outcomes.</div></div><div><h3>Results</h3><div>Only one randomized controlled trial and one observational study have directly evaluated colchicine after TAVR. Both demonstrated reductions in inflammatory biomarkers and signals toward improved conduction-related parameters, but clinical endpoints such as pacemaker implantation, sustained arrhythmias, and imaging-confirmed leaflet thrombosis remain insufficiently studied. Mechanistic and perioperative cardiac evidence from non-TAVR settings supports colchicine’s potential by targeting inflammasome activity, microtubule regulation, and early thrombo-inflammatory remodeling.</div></div><div><h3>Conclusions</h3><div>Colchicine is a promising adjunctive strategy for attenuating inflammation-related complications after TAVR. Its multimodal actions align with the pathways implicated in conduction disturbances, atrial fibrillation, and leaflet thrombosis. However, current evidence is preliminary, with only two post-TAVR intervention studies available. Larger trials are needed to determine whether colchicine can translate mechanistic advantages into clinically meaningful improvements in post-TAVR outcomes.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"29 ","pages":"Article 200575"},"PeriodicalIF":2.1,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146057468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comments on: “Association between body roundness index trajectories and the risk of cardiometabolic multimorbidity in Chinese middle-aged and older adults: Evidence from the China health and retirement longitudinal study” 评论：“中国中老年人身体圆度指数轨迹与心血管代谢多病风险的关系：来自中国健康与退休纵向研究的证据”

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-08 DOI: 10.1016/j.ijcrp.2026.200578

Bin Cao , Bingning Ma

引用次数: 0

Impact of an assessment form on promoting in-hospital initiation of sodium–glucose cotransporter-2 inhibitors in hospitalized patients with heart failure 一种评估表格对促进住院心力衰竭患者开始使用钠-葡萄糖共转运蛋白-2抑制剂的影响

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-08 DOI: 10.1016/j.ijcrp.2026.200577

Takuya Okamoto , Koichiro Matsumura , Hiroyo Miyata , Yuta Kimoto , Kazue Hamamura , Keiko Kato , Shohei Hakozaki , Eijiro Yagi , Masafumi Ueno , Kimiko Fujiwara , Manabu Takegami , Gaku Nakazawa

Background

Despite the established benefits of in-hospital administration of sodium–glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure (HF), their implementation remains insufficient. To investigate whether the use of an Assessment Form influences SGLT2i prescriptions at discharge among hospitalized patients with HF.

Methods

We retrospectively analyzed consecutive patients with HF from a prospective registry between September 2024 and August 2025 after the implementation of an Assessment Form. Patients who died during hospitalization were excluded. The Assessment Form was completed collaboratively by physicians and nurses. Physicians checked whether guideline-directed medical therapy (including SGLT2i) had been prescribed, and documented the reasons if not initiated, while nurses evaluated the patients’ pre-hospital living conditions and self-care abilities. The primary endpoint was the prescription rate of SGLT2i at discharge according to the Assessment Form.

Results

Among the 208 analyzed patients (median age, 81 years [range, 75–87] years, 59 % male], the Assessment Form was used by 61.1 % (127/208). The prescription rate of SGLT2i at discharge was significantly higher in patients who completed the Assessment Form than in those who did not (65.4 % vs. 45.7 %, p < 0.01). Multivariable logistic regression identified use of the Assessment Form as an independent factor associated with SGLT2i prescription at discharge (odds ratio 2.12, 95 % confidence interval 1.04–4.32, p = 0.03).

Conclusion

Implementation of an Assessment Form was associated with increased initiation of in-hospital SGLT2i therapy. The active use of such structured forms may help promote adherence to guideline-directed therapies during hospitalization for HF.

背景：尽管在心力衰竭（HF）患者中使用钠-葡萄糖共转运蛋白-2抑制剂（SGLT2i）已确立了益处，但其实施仍然不足。目的：探讨评估表的使用是否影响心衰住院患者出院时的SGLT2i处方。方法回顾性分析2024年9月至2025年8月期间前瞻性登记的连续HF患者。住院期间死亡的患者被排除在外。评估表由医生和护士共同完成。医生检查是否已经开了指南指导的药物治疗（包括SGLT2i），并记录了如果没有开始的原因，而护士则评估患者院前生活条件和自我护理能力。主要终点为出院时SGLT2i的处方率。结果在分析的208例患者中（中位年龄81岁[范围75 ~ 87]岁，男性59%），61.1%（127/208）使用了《评估表》。完成评估表的患者出院时SGLT2i处方率显著高于未完成评估表的患者（65.4% vs. 45.7%, p < 0.01）。多变量logistic回归发现，使用评估表是与出院时SGLT2i处方相关的独立因素（优势比2.12,95%置信区间1.04-4.32,p = 0.03）。结论评估表格的实施与院内SGLT2i治疗的开始增加有关。积极使用这种结构化表格可能有助于促进心衰住院期间对指导治疗的依从性。

{"title":"Impact of an assessment form on promoting in-hospital initiation of sodium–glucose cotransporter-2 inhibitors in hospitalized patients with heart failure","authors":"Takuya Okamoto , Koichiro Matsumura , Hiroyo Miyata , Yuta Kimoto , Kazue Hamamura , Keiko Kato , Shohei Hakozaki , Eijiro Yagi , Masafumi Ueno , Kimiko Fujiwara , Manabu Takegami , Gaku Nakazawa","doi":"10.1016/j.ijcrp.2026.200577","DOIUrl":"10.1016/j.ijcrp.2026.200577","url":null,"abstract":"<div><h3>Background</h3><div>Despite the established benefits of in-hospital administration of sodium–glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure (HF), their implementation remains insufficient. To investigate whether the use of an Assessment Form influences SGLT2i prescriptions at discharge among hospitalized patients with HF.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed consecutive patients with HF from a prospective registry between September 2024 and August 2025 after the implementation of an Assessment Form. Patients who died during hospitalization were excluded. The Assessment Form was completed collaboratively by physicians and nurses. Physicians checked whether guideline-directed medical therapy (including SGLT2i) had been prescribed, and documented the reasons if not initiated, while nurses evaluated the patients’ pre-hospital living conditions and self-care abilities. The primary endpoint was the prescription rate of SGLT2i at discharge according to the Assessment Form.</div></div><div><h3>Results</h3><div>Among the 208 analyzed patients (median age, 81 years [range, 75–87] years, 59 % male], the Assessment Form was used by 61.1 % (127/208). The prescription rate of SGLT2i at discharge was significantly higher in patients who completed the Assessment Form than in those who did not (65.4 % vs. 45.7 %, <em>p</em> < 0.01). Multivariable logistic regression identified use of the Assessment Form as an independent factor associated with SGLT2i prescription at discharge (odds ratio 2.12, 95 % confidence interval 1.04–4.32, <em>p</em> = 0.03).</div></div><div><h3>Conclusion</h3><div>Implementation of an Assessment Form was associated with increased initiation of in-hospital SGLT2i therapy. The active use of such structured forms may help promote adherence to guideline-directed therapies during hospitalization for HF.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200577"},"PeriodicalIF":2.1,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk for coronary artery disease among individuals with normal low-density lipoprotein cholesterol (LDL-C) levels 低密度脂蛋白胆固醇（LDL-C）水平正常的人患冠状动脉疾病的风险

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-08 DOI: 10.1016/j.ijcrp.2026.200572

Zhuqing Shi , Ashley J. Mulford , Jun Wei , Huy Tran , Annabelle Ashworth , S. Lilly Zheng , Brian T. Helfand , David Duggan , Henry M. Dunnenberger , Peter J. Hulick , David J. Davidson , Arman Qamar , Alan R. Sanders , Jianfeng Xu

Background

Low-density lipoprotein cholesterol (LDL-C) levels <100 mg/dL are generally considered normal. We tested the controversial hypothesis that a subset of individuals with ‘normal’ LDL-C levels may have a non-negligible risk of coronary artery disease (CAD) due to inherited factors, including monogenic variants and polygenic risk scores (PGS).

Methods

A retrospective analysis of a prospective cohort from the Genomic Health Initiative at Endeavor Health, including 7880 participants without a prior diagnosis of CAD and not on statins at recruitment. Participants were stratified by baseline LDL-C levels and followed for incident CAD. The association of CAD risk with carrier status for pathogenic/likely pathogenic (P/LP) variants in LDLR, APOB, and PCSK9, as well as with PGS, was tested using Cox regression models adjusted for relevant covariates at baseline.

Results

Among participants, 31.2 % had LDL-C <100 mg/dL (normal), 39.5 % had LDL-C 100–129 mg/dL, and 29.3 % had LDL-C ≥130 mg/dL. Over a median follow-up of 8 years, CAD was diagnosed in 5.3 %, 6.9 %, and 7.6 % of participants in these LDL-C groups, respectively. Among those with normal LDL-C, CAD incidence rose to 9.5 % in individuals with high genetic risk (P/LP variants and/or high PGS). Genetic risk was significantly associated with CAD in multivariable models (P < 0.001). These findings were consistent in subjects of European and non-European ancestry.

Conclusion

Individuals with ‘normal’ LDL-C levels can have substantial CAD risk if they carry high genetic risk. These findings underscore the importance of incorporating genetic information into CAD risk assessment, even among those with traditionally normal lipid profiles.

背景：低密度脂蛋白胆固醇（LDL-C）水平100 mg/dL通常被认为是正常的。我们测试了一个有争议的假设，即由于遗传因素，包括单基因变异和多基因风险评分（PGS），一小部分LDL-C水平“正常”的个体可能具有不可忽视的冠状动脉疾病（CAD）风险。方法对来自Endeavor Health基因组健康计划的前瞻性队列进行回顾性分析，包括7880名招募时未诊断为CAD且未服用他汀类药物的参与者。参与者按基线LDL-C水平分层，并随访冠心病事件。CAD风险与LDLR、APOB和PCSK9中致病/可能致病（P/LP）变异的携带者状态以及与PGS的关系，使用Cox回归模型在基线上调整相关协变量进行了测试。结果31.2%的参与者LDL-C≥100 mg/dL（正常），39.5%的参与者LDL-C≥100 - 129 mg/dL， 29.3%的参与者LDL-C≥130 mg/dL。在中位8年的随访中，这些LDL-C组中分别有5.3%、6.9%和7.6%的参与者被诊断为CAD。在LDL-C正常的人群中，具有高遗传风险（P/LP变异和/或高PGS）的冠心病发病率上升至9.5%。在多变量模型中，遗传风险与CAD显著相关（P < 0.001）。这些发现在欧洲和非欧洲血统的研究对象中都是一致的。结论：LDL-C水平“正常”的个体如果携带较高的遗传风险，则有较大的冠心病风险。这些发现强调了将遗传信息纳入冠心病风险评估的重要性，即使是那些传统上血脂正常的人。

{"title":"Risk for coronary artery disease among individuals with normal low-density lipoprotein cholesterol (LDL-C) levels","authors":"Zhuqing Shi , Ashley J. Mulford , Jun Wei , Huy Tran , Annabelle Ashworth , S. Lilly Zheng , Brian T. Helfand , David Duggan , Henry M. Dunnenberger , Peter J. Hulick , David J. Davidson , Arman Qamar , Alan R. Sanders , Jianfeng Xu","doi":"10.1016/j.ijcrp.2026.200572","DOIUrl":"10.1016/j.ijcrp.2026.200572","url":null,"abstract":"<div><h3>Background</h3><div>Low-density lipoprotein cholesterol (LDL-C) levels <100 mg/dL are generally considered normal. We tested the controversial hypothesis that a subset of individuals with ‘normal’ LDL-C levels may have a non-negligible risk of coronary artery disease (CAD) due to inherited factors, including monogenic variants and polygenic risk scores (PGS).</div></div><div><h3>Methods</h3><div>A retrospective analysis of a prospective cohort from the Genomic Health Initiative at Endeavor Health, including 7880 participants without a prior diagnosis of CAD and not on statins at recruitment. Participants were stratified by baseline LDL-C levels and followed for incident CAD. The association of CAD risk with carrier status for pathogenic/likely pathogenic (P/LP) variants in <em>LDLR</em>, <em>APOB</em>, and <em>PCSK9</em>, as well as with PGS, was tested using Cox regression models adjusted for relevant covariates at baseline.</div></div><div><h3>Results</h3><div>Among participants, 31.2 % had LDL-C <100 mg/dL (normal), 39.5 % had LDL-C 100–129 mg/dL, and 29.3 % had LDL-C ≥130 mg/dL. Over a median follow-up of 8 years, CAD was diagnosed in 5.3 %, 6.9 %, and 7.6 % of participants in these LDL-C groups, respectively. Among those with normal LDL-C, CAD incidence rose to 9.5 % in individuals with high genetic risk (P/LP variants and/or high PGS). Genetic risk was significantly associated with CAD in multivariable models (<em>P</em> < 0.001). These findings were consistent in subjects of European and non-European ancestry.</div></div><div><h3>Conclusion</h3><div>Individuals with ‘normal’ LDL-C levels can have substantial CAD risk if they carry high genetic risk. These findings underscore the importance of incorporating genetic information into CAD risk assessment, even among those with traditionally normal lipid profiles.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200572"},"PeriodicalIF":2.1,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship between nutrition status and muscle mass and its impact on 1-year mortality in patients with aortic stenosis undergoing transcatheter aortic valve implantation 经导管主动脉瓣置入术主动脉瓣狭窄患者营养状况与肌肉质量的关系及其对1年死亡率的影响

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-07 DOI: 10.1016/j.ijcrp.2026.200573

Hiroyo Miyata , Koichiro Matsumura , Kazue Hamamura , Masakazu Yasuda , Shohei Hakozaki , Kyohei Onishi , Eijiro Yagi , Kosuke Fujita , Katsumi Kajihara , Teruyoshi Amagai , Masafumi Ueno , Gaku Nakazawa

Background

We aimed to evaluate whether dual assessment of nutritional status and muscle mass could enhance the prediction of 1-year mortality in patients undergoing transcatheter aortic valve implantation (TAVI).

Methods

This retrospective study included 312 consecutive patients who underwent TAVI for aortic stenosis. Nutritional status was determined by calculating the geriatric nutritional risk index (GNRI), with a cutoff of 98. Muscle mass was calculated from the psoas muscle volume index (PMVI). Patients were stratified into three groups based on GNRI and PMVI: Low, middle, and high groups (GNRI: < 98, < 98, and > 98; and below, or below, and above the sex-specific median PMVI, respectively). The primary endpoint was all-cause mortality within 1-year.

Results

After exclusion, 259 patients were included in the analysis, and 22 died within 1-year. Kaplan-Meier survival curves showed a significant difference in all-cause mortality within 1-year among the three groups. Multivariate analysis of the Cox proportional hazards model for factors related to all-cause mortality within 1-year showed no significant association in the middle group when the high group was used as a reference, and the low group was independently associated.

Conclusion

The combined assessment of nutritional status and muscle mass improves the identification of high-risk patients undergoing transcatheter aortic valve implantation and enhances the prognostic accuracy beyond individual markers. This approach may aid in refining the risk stratification and tailoring the perioperative management of patients undergoing TAVI.

背景：我们旨在评估营养状况和肌肉质量的双重评估是否可以增强对经导管主动脉瓣植入术（TAVI）患者1年死亡率的预测。方法本回顾性研究纳入312例连续接受TAVI治疗主动脉瓣狭窄的患者。通过计算老年人营养风险指数（GNRI）来确定营养状况，截止值为98。肌肉质量由腰肌体积指数（PMVI）计算。根据GNRI和PMVI将患者分为三组：低、中、高组（GNRI分别为<； 98、< 98、>； 98及低于或低于、高于性别特异性中位PMVI）。主要终点是1年内的全因死亡率。结果经排除后，259例患者纳入分析，其中22例在1年内死亡。Kaplan-Meier生存曲线显示三组1年内全因死亡率有显著差异。Cox比例风险模型对1年内全因死亡率相关因素的多因素分析显示，以高组为参照，中组无显著相关性，低组独立相关。结论营养状况和肌肉质量的联合评估提高了对经导管主动脉瓣置入术高危患者的识别，提高了预后的准确性。这种方法可能有助于完善风险分层和定制TAVI患者的围手术期管理。

{"title":"Relationship between nutrition status and muscle mass and its impact on 1-year mortality in patients with aortic stenosis undergoing transcatheter aortic valve implantation","authors":"Hiroyo Miyata , Koichiro Matsumura , Kazue Hamamura , Masakazu Yasuda , Shohei Hakozaki , Kyohei Onishi , Eijiro Yagi , Kosuke Fujita , Katsumi Kajihara , Teruyoshi Amagai , Masafumi Ueno , Gaku Nakazawa","doi":"10.1016/j.ijcrp.2026.200573","DOIUrl":"10.1016/j.ijcrp.2026.200573","url":null,"abstract":"<div><h3>Background</h3><div>We aimed to evaluate whether dual assessment of nutritional status and muscle mass could enhance the prediction of 1-year mortality in patients undergoing transcatheter aortic valve implantation (TAVI).</div></div><div><h3>Methods</h3><div>This retrospective study included 312 consecutive patients who underwent TAVI for aortic stenosis. Nutritional status was determined by calculating the geriatric nutritional risk index (GNRI), with a cutoff of 98. Muscle mass was calculated from the psoas muscle volume index (PMVI). Patients were stratified into three groups based on GNRI and PMVI: Low, middle, and high groups (GNRI: < 98, < 98, and > 98; and below, or below, and above the sex-specific median PMVI, respectively). The primary endpoint was all-cause mortality within 1-year.</div></div><div><h3>Results</h3><div>After exclusion, 259 patients were included in the analysis, and 22 died within 1-year. Kaplan-Meier survival curves showed a significant difference in all-cause mortality within 1-year among the three groups. Multivariate analysis of the Cox proportional hazards model for factors related to all-cause mortality within 1-year showed no significant association in the middle group when the high group was used as a reference, and the low group was independently associated.</div></div><div><h3>Conclusion</h3><div>The combined assessment of nutritional status and muscle mass improves the identification of high-risk patients undergoing transcatheter aortic valve implantation and enhances the prognostic accuracy beyond individual markers. This approach may aid in refining the risk stratification and tailoring the perioperative management of patients undergoing TAVI.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200573"},"PeriodicalIF":2.1,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical efficacy comparison between extracorporeal shock wave therapy and enhanced external counterpulsation for coronary heart disease 体外冲击波治疗与强化体外反搏治疗冠心病的临床疗效比较

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-07 DOI: 10.1016/j.ijcrp.2026.200574

Ting Zhao , Suping Lan , Yun Zhang , Yupin Dong , Lunyan Lu , Xu Chen , Song Li , Yuncheng Li , Shen Wang , Yue Wang , Xiaofan Wu , Xinjian Li

Objective

This study aims to evaluate the clinical efficacy of extracorporeal cardiac shock wave therapy(CSWT) and enhanced external counterpulsation(EECP),both individually and in combination,in patients with coronary artery disease(CAD),and to explore effective non-invasive treatment strategies.

Methods

A total of 259 patients with CAD admitted between January 2023 and June 2024 were enrolled and randomly assigned to four groups:the Control group(n = 65) received conventional medication only; the EECP group(n = 65) received conventional medication plus EECP treatment(EECP; total duration 36 h); the CSWT group(n = 64) received conventional medication plus CSWT therapy(CSWT; total duration 4.5 h); and the Combination group(EECP + CSWT group,n = 65) received conventional medication combined with both CSWT(4.5 h) and EECP(36 h).Coronary stenosis severity, cardiac function indices, blood biochemistry and other indicators were evaluated at baseline and 12 months after treatment.

Results

Baseline characteristics showed no significant differences among the groups(P > 0.05). After 12 months of treatment, the Gensini score of the EECP + CSWT group decreased by 20 points, which was significantly lower than that of the EECP group (−5 points, P < 0.05), the CSWT group (−15 points, P < 0.05) and the control group (−0.5 points, P < 0.05). Secondly, compared with the control group, the CSWT group, EECP group and EECP + CSWT group showed more significant improvements in cardiac function and blood biochemical parameters (P < 0.05). The EECP + CSWT group exhibited the most pronounced therapeutic efficacy, followed by the EECP group and the CSWT group; all three intervention groups were significantly superior to the Control group (P < 0.05).

Conclusion

Both CSWT and EECP effectively improve the severity of coronary artery disease, cardiac function,and blood biochemical parameters in CAD patients.The combination of these two therapies demonstrates synergistic effects, yielding significantly superior outcomes compared to either monotherapy.

目的评价体外心脏冲击波治疗（CSWT）和体外强化反搏（EECP）单独或联合治疗冠心病（CAD）的临床疗效，探讨有效的无创治疗策略。方法纳入2023年1月至2024年6月期间收治的CAD患者259例，随机分为4组：对照组（n = 65）仅接受常规药物治疗；EECP组（65例）给予常规药物治疗加EECP治疗（EECP，总持续时间36 h）；CSWT组（n = 64）采用常规药物加CSWT治疗（CSWT，总持续时间4.5 h）；联合组（EECP + CSWT组，n = 65）采用常规药物联合CSWT（4.5 h）和EECP（36 h）治疗。在治疗前及治疗后12个月评估冠状动脉狭窄严重程度、心功能指标、血液生化等指标。结果两组患者基线特征差异无统计学意义（P > 0.05）。治疗12个月后，EECP + CSWT组Gensini评分下降20分，显著低于EECP组（- 5分，P < 0.05）、CSWT组（- 15分，P < 0.05）和对照组（- 0.5分，P < 0.05）。其次，与对照组相比，CSWT组、EECP组和EECP + CSWT组心功能和血液生化指标改善更为显著（P < 0.05）。EECP + CSWT组治疗效果最显著，其次为EECP组和CSWT组；三个干预组均显著优于对照组（P < 0.05）。结论CSWT和EECP均能有效改善冠心病患者冠状动脉病变严重程度、心功能及血液生化指标。这两种疗法的结合显示出协同效应，与任何单一疗法相比，产生明显更好的结果。

{"title":"Clinical efficacy comparison between extracorporeal shock wave therapy and enhanced external counterpulsation for coronary heart disease","authors":"Ting Zhao , Suping Lan , Yun Zhang , Yupin Dong , Lunyan Lu , Xu Chen , Song Li , Yuncheng Li , Shen Wang , Yue Wang , Xiaofan Wu , Xinjian Li","doi":"10.1016/j.ijcrp.2026.200574","DOIUrl":"10.1016/j.ijcrp.2026.200574","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to evaluate the clinical efficacy of extracorporeal cardiac shock wave therapy(CSWT) and enhanced external counterpulsation(EECP),both individually and in combination,in patients with coronary artery disease(CAD),and to explore effective non-invasive treatment strategies.</div></div><div><h3>Methods</h3><div>A total of 259 patients with CAD admitted between January 2023 and June 2024 were enrolled and randomly assigned to four groups:the Control group(n = 65) received conventional medication only; the EECP group(n = 65) received conventional medication plus EECP treatment(EECP; total duration 36 h); the CSWT group(n = 64) received conventional medication plus CSWT therapy(CSWT; total duration 4.5 h); and the Combination group(EECP + CSWT group,n = 65) received conventional medication combined with both CSWT(4.5 h) and EECP(36 h).Coronary stenosis severity, cardiac function indices, blood biochemistry and other indicators were evaluated at baseline and 12 months after treatment.</div></div><div><h3>Results</h3><div>Baseline characteristics showed no significant differences among the groups(P > 0.05). After 12 months of treatment, the Gensini score of the EECP + CSWT group decreased by 20 points, which was significantly lower than that of the EECP group (−5 points, P < 0.05), the CSWT group (−15 points, P < 0.05) and the control group (−0.5 points, P < 0.05). Secondly, compared with the control group, the CSWT group, EECP group and EECP + CSWT group showed more significant improvements in cardiac function and blood biochemical parameters (P < 0.05). The EECP + CSWT group exhibited the most pronounced therapeutic efficacy, followed by the EECP group and the CSWT group; all three intervention groups were significantly superior to the Control group (P < 0.05).</div></div><div><h3>Conclusion</h3><div>Both CSWT and EECP effectively improve the severity of coronary artery disease, cardiac function,and blood biochemical parameters in CAD patients.The combination of these two therapies demonstrates synergistic effects, yielding significantly superior outcomes compared to either monotherapy.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200574"},"PeriodicalIF":2.1,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

“Bridging the clinical, molecular and genetic perspectives on myocarditis in post-COVID-19 era” “连接后covid -19时代心肌炎的临床、分子和遗传学观点”

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-07 DOI: 10.1016/j.ijcrp.2026.200576

Siddharth Birla , Arshia Angural , Arya Madathumchalil , Ritika V. Shende , Sharvani V. Shastry , Pallavi Kanyappa Shekar , Manjappa Mahadevappa , Prashant Vishwanath , Akila Prashant

Myocarditis is a non-familial inflammatory manifestation of the myocardium, primarily induced by viral infections, but it may also stem from bacterial pathogens, autoimmune disorders, or adverse drug reactions. Its diagnosis remains challenging due to heterogeneous and often non-specific clinical presentations. Recent epidemiological studies have indicated a markedly increased incidence of myocarditis following SARS-CoV-2 infection and mRNA COVID-19 vaccinations (to a lesser extent) compared to pre-pandemic statistics. While a significant number of cases follow a mild and self-limiting disease course, severe manifestations can lead to arrhythmias, heart failure, or even sudden cardiac death. Importantly, accumulating evidence indicates that even mild myocarditis confers an elevated long-term risk of adverse cardiovascular outcomes. Beyond clinical and imaging-based observations, recent advances highlight a critical role for host genetic susceptibility in modulating immune responses, myocardial injury, and disease severity. This review provides a comprehensive synthesis of the etiology, pathophysiological mechanisms, clinical spectrum, diagnostic approaches, and evidence-based management of COVID-19-associated myocarditis, while critically integrating emerging genetic and transcriptomic insights that may explain disease heterogeneity, variable inter-individual susceptibility, and long-term prognosis. By bridging clinical aspects with molecular and genetic frameworks, this review underscores the importance of personalized risk stratification, vigilant post-recovery surveillance, and targeted preventive strategies in the post-pandemic era.

心肌炎是心肌的一种非家族性炎症表现，主要由病毒感染引起，但也可能源于细菌病原体、自身免疫性疾病或药物不良反应。由于异质性和非特异性的临床表现，其诊断仍然具有挑战性。最近的流行病学研究表明，与大流行前的统计数据相比，SARS-CoV-2感染和mRNA - COVID-19疫苗接种后心肌炎的发病率（在较小程度上）显着增加。虽然相当数量的病例遵循轻微和自限性的病程，但严重的表现可导致心律失常，心力衰竭，甚至心源性猝死。重要的是，越来越多的证据表明，即使是轻微的心肌炎也会增加不良心血管结局的长期风险。除了临床和基于成像的观察，最近的进展强调了宿主遗传易感性在调节免疫反应、心肌损伤和疾病严重程度方面的关键作用。本综述全面综合了covid -19相关心肌炎的病因学、病理生理机制、临床谱、诊断方法和循证管理，同时批判性地整合了新出现的遗传和转录组学见解，这些见解可能解释疾病异质性、可变个体间易感性和长期预后。通过将临床方面与分子和遗传框架联系起来，本综述强调了在大流行后时代个性化风险分层、警惕的康复后监测和有针对性的预防策略的重要性。

{"title":"“Bridging the clinical, molecular and genetic perspectives on myocarditis in post-COVID-19 era”","authors":"Siddharth Birla , Arshia Angural , Arya Madathumchalil , Ritika V. Shende , Sharvani V. Shastry , Pallavi Kanyappa Shekar , Manjappa Mahadevappa , Prashant Vishwanath , Akila Prashant","doi":"10.1016/j.ijcrp.2026.200576","DOIUrl":"10.1016/j.ijcrp.2026.200576","url":null,"abstract":"<div><div>Myocarditis is a non-familial inflammatory manifestation of the myocardium, primarily induced by viral infections, but it may also stem from bacterial pathogens, autoimmune disorders, or adverse drug reactions. Its diagnosis remains challenging due to heterogeneous and often non-specific clinical presentations. Recent epidemiological studies have indicated a markedly increased incidence of myocarditis following SARS-CoV-2 infection and mRNA COVID-19 vaccinations (to a lesser extent) compared to pre-pandemic statistics. While a significant number of cases follow a mild and self-limiting disease course, severe manifestations can lead to arrhythmias, heart failure, or even sudden cardiac death. Importantly, accumulating evidence indicates that even mild myocarditis confers an elevated long-term risk of adverse cardiovascular outcomes. Beyond clinical and imaging-based observations, recent advances highlight a critical role for host genetic susceptibility in modulating immune responses, myocardial injury, and disease severity. This review provides a comprehensive synthesis of the etiology, pathophysiological mechanisms, clinical spectrum, diagnostic approaches, and evidence-based management of COVID-19-associated myocarditis, while critically integrating emerging genetic and transcriptomic insights that may explain disease heterogeneity, variable inter-individual susceptibility, and long-term prognosis. By bridging clinical aspects with molecular and genetic frameworks, this review underscores the importance of personalized risk stratification, vigilant post-recovery surveillance, and targeted preventive strategies in the post-pandemic era.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200576"},"PeriodicalIF":2.1,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0